Jiangsu wuzhong(600200)2022-04-26 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥444,334,210.73, representing a decrease of 18.42% compared to the same period last year[6]. - The net profit attributable to shareholders was ¥7,616,890.35, down 91.98% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,564,967.59, an increase of 147.52% compared to the previous year[6]. - Basic and diluted earnings per share were both ¥0.011, down 91.96% compared to the same period last year[9]. - Total operating revenue for Q1 2022 was CNY 444,334,210.73, down 18.4% from CNY 544,676,711.15 in Q1 2021[35]. - Net profit for Q1 2022 was CNY 7,016,937.24, a significant decline from CNY 94,976,017.36 in Q1 2021[35]. Cash Flow - The net cash flow from operating activities was ¥43,601,145.05, a decrease of 91.72% year-on-year[6]. - In Q1 2022, the net cash flow from operating activities was ¥43,601,145.05, a significant decrease of 91.7% compared to ¥526,509,617.96 in Q1 2021[41]. - Total cash inflow from investment activities was ¥86,880,669.00, down from ¥200,216,527.29 in the previous year, reflecting a decline of 56.7%[43]. - Cash inflow from financing activities totaled ¥572,340,828.62, an increase of 9.3% compared to ¥523,548,121.51 in Q1 2021[43]. - The total cash and cash equivalents at the end of Q1 2022 stood at ¥1,337,683,178.90, slightly down from ¥1,390,736,406.74 at the end of Q1 2021[43]. - Cash received from sales and services in Q1 2022 was ¥1,529,661,484.00, a decrease of 25.4% from ¥2,053,130,900.71 in Q1 2021[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,704,724,379.12, a decrease of 1.43% from the end of the previous year[9]. - The total current assets as of March 31, 2022, were RMB 2,634,823,944.40, slightly down from RMB 2,684,319,610.62 at the end of 2021, reflecting a decrease of approximately 1.8%[26]. - The company's non-current assets totaled RMB 1,069,900,434.72 as of March 31, 2022, compared to RMB 1,074,018,034.94 at the end of 2021, showing a decrease of about 0.4%[26]. - Total liabilities decreased to CNY 1,806,471,158.74 in Q1 2022 from CNY 1,881,410,098.21 in Q1 2021, a reduction of 4.0%[31]. - Total equity increased to CNY 1,898,253,220.38 in Q1 2022 from CNY 1,876,927,547.35 in Q1 2021, an increase of 1.1%[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 76,000[14]. - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., held 17.24% of the shares, with 92,900,000 shares pledged[14]. Research and Development - The company increased its R&D expenses by 332.17% during the reporting period[13]. - Research and development expenses increased to CNY 8,136,954.52 in Q1 2022, compared to CNY 1,882,812.81 in Q1 2021, reflecting a growth of 331.5%[35]. Other Financial Metrics - The return on equity (ROE) was 0.41%, down 4.60% year-on-year[9]. - Financial expenses rose to CNY 19,308,006.66 in Q1 2022, compared to CNY 18,417,168.13 in Q1 2021, an increase of 4.8%[35]. - The company's retained earnings showed a slight improvement, with a deficit of CNY -332,797,898.60 in Q1 2022 compared to CNY -340,414,788.95 in Q1 2021[31]. Investments and Subsidiaries - The company established a wholly-owned subsidiary in Hong Kong with a registered capital of USD 1 million during the reporting period[20]. - The company’s investment in Hangzhou Lingjian Medical Technology Partnership increased by RMB 6.8 million, raising the total contribution to RMB 117.2 million[21].